Deb-Chatterji, Milani http://orcid.org/0000-0003-4282-3518
Flottmann, Fabian
Leischner, Hannes
Alegiani, Anna
Brekenfeld, Caspar
Fiehler, Jens
Gerloff, Christian
Thomalla, Götz
Article History
Received: 4 March 2019
Accepted: 25 October 2019
First Online: 23 December 2019
Compliance with ethical guidelines
:
: M. Deb-Chatterji, F. Flottmann, H. Leischner and C. Brekenfeld declare that they have no competing interests. A. Alegiani reports fees as speaker from Bayer Vital. J. Fiehler reports personal fees from Cerenovus, Penumbra, Route 92 Medical, grants and personal fees from Acandis, Medtronic, Microvention. C. Gerloff reports fees as speaker and/or scientific advisory board member from Actitor Biotech, Amgen, Bayer Healthcare, Boehringer Ingelheim, Prediction Biosciences, Sanofi Aventis. G. Thomalla reports personal fees from Acandis, grants and personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from Bristol-Myers Squibb/Pfizer, personal fees from Daichi Sankyo, personal fees from Stryker, outside the submitted work.
: This study, conducted on human subjects, was approved by the local ethics committee (Hamburg, Germany; MC-039/16) and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All patients or their proxies, as appropriate, gave written informed consent prior to inclusion in the study. Consent was waived if patients died before consent could be obtained or lacked the capacity to give consent and no proxy was available.